louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT02418637: Pilot Study Testing Feasibility of Health Screening at Farm Site
Official title: Worksite Screening for Cardiovascular Risk Factors Among Migrant Agricultural Workers
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Diabetes Screening
Hyperlipidemia Screening
Hypertension Screening
Keywords: worksite
screen
migrant
agricultural
worker
hypertension
Hyperlipidemia
diabetes
feasibility
Lead sponsor: Mayo Clinic
Sponsor class: OTHER
First posted: 2015-04-16
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: PREVENTION

Brief summary: Test the feasibility of performing worksite screening of Hypertension, Diabetes and Hyperlipidemia for six months

Detailed description: The investigators will be visiting farmers at the worksite monthly for six month and perform cardiovascular risk factors screening: blood pressure, blood glucose, glycosylated hemoglobin and cholesterol.

At the end of this intervention, the investigators will test the feasibility of this approach among this specific population through questionnaires.

Eligibility criteria: Inclusion Criteria:

* 18 years and older
* agricultural workers and farm owners

Exclusion Criteria:

* None

Primary outcomes:
measure: Feasibility (Likert scale)
timeFrame: After six months of the intervention, the outcome will be assessed on the last site visit via questionnaire
Secondary outcomes:
Other outcomes:
Locations:
city: Rochester
country: United States
facility: Mayo Clinic in Rochester
state: Minnesota
Study officials:
affiliation: Mayo Clinic
name: M Murad, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Rajjo T, Mohammed K, Rho J, Murad MH. On-the-farm cardiovascular risk screening among migrant agricultural workers in Southeast Minnesota: a pilot prospective study. BMJ Open. 2018 Jul 30;8(7):e019547. doi: 10.1136/bmjopen-2017-019547.
Clinical trial NCT02041637: Unknown Cause of Acute Liver Failure
Official title: Unknown Cause of Acute Liver Failure: Determination of Early Mortality Predictive Factors
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Liver Failure
Unknown Etiology
Keywords: liver failure
etiology
liver transplantation
Lead sponsor: Assistance Publique - Hôpitaux de Paris
Sponsor class: OTHER
First posted: 2014-01-22
Enrollment: 72
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Acute liver failure without cause identified at admission

Brief summary: The purpose of the study is to evaluate the outcome and to determine predictive factors of patients admitted in a context of acute liver failure without identified cause.

Detailed description: Methodology: Multicentric French national cohort with prospective collection of data and constitution of biobank, in patients hospitalized in a context of acute liver failure without known cause at admission. Follow-up during 3 months for each patients. The primary objective is to determine predictive factors of early mortality. This study is an observational cohort and patients will received standard care during the follow-up.

Eligibility criteria: Inclusion Criteria:

* Acute liver failure defined by a PT\<50% or INR\>1.5;
* with or without hepatic encephalopathy;
* without cause identified at admission, and non A non B hepatitis;
* age\>18 year old;
* signed an informed consent.

Exclusion Criteria:

* chronic liver disease;
* Patient under guardianship

Primary outcomes:
measure: mortality
timeFrame: At 3 months
Secondary outcomes:
measure: Liver transplantation rate
timeFrame: At 3 months
measure: Overall survival rate
timeFrame: At 3 months
measure: post-transplant mortality rate
timeFrame: At 3 months
Other outcomes:
Locations:
city: Villejuif
country: France
facility: AP-HP, Paul Brousse Hospital, Centre Hepato-Biliaire
Study officials:
affiliation: Assistance Publique - Hôpitaux de Paris
name: Audrey COILLY, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Assistance Publique - Hôpitaux de Paris
name: Didier Samuel, MD, PhD
role: STUDY_DIRECTOR
References:
Clinical trial NCT04008537: Daily Imaging, Target Identification, and Simulated Computed Tomography-Based Stereotactic Adaptive Radiotherapy Workflow in a Novel Ring Gantry Radiotherapy Device
Official title: A Pilot Study of Daily Imaging, Target Identification, and Simulated Computed Tomography-Based Stereotactic Adaptive Radiotherapy Workflow in a Novel Ring Gantry Radiotherapy Device
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Cancer of Pancreas
Cancer of Pelvis
Cancer of Abdomen
Cancer of Thorax
Lead sponsor: Washington University School of Medicine
Sponsor class: OTHER
Collaborators: name: Varian Medical Systems
First posted: 2019-07-05
Enrollment: 37
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DEVICE_FEASIBILITY

Brief summary: The investigators propose here to evaluate the feasibility of a novel cone-beam CT (CBCT)-guided online adaptive radiotherapy (ART) workflow on the Halcyon device.


Eligibility criteria: Inclusion Criteria:

* At least one disease site deemed to be suitable for simulated treatment with online adaptive radiotherapy per radiation oncology evaluation.
* Scheduled to receive radiation therapy to the thorax (n = 8), pancreas (n = 8), non-pancreas abdomen (n = 8), or pelvis (n = 8).
* At least 18 years of age
* Able to understand and willing to sign an IRB-approved written informed consent document.

Exclusion Criteria:

* Pregnant and/or breastfeeding. Women of childbearing potential must have a negative pregnancy test within 14 days of study entry. If pregnancy test is not clinically indicated as determined by treating physician or protocol PI, documentation of this exception is sufficient in lieu of a pregnancy test.

Primary outcomes:
measure: Feasibility of the device as measured by successful completion of the full CBCT-guided online ART workflow, from volumetric imaging through phantom delivery in at least 90% of attempted fractions
timeFrame: Completion of ART workflow in all enrolled participants (estimated to be 30 months)
Secondary outcomes:
Other outcomes:
Locations:
city: Saint Louis
country: United States
facility: Washington University School of Medicine
state: Missouri
Study officials:
affiliation: Washington University School of Medicine
name: Lauren Henke, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03214237: A Cross-sectional Study of the Oral Health of Elderly Inpatients in Acute and Subacute Hospitals in Northumberland and North Tyneside
Official title: A Cross-sectional Study of the Oral Health of Elderly Inpatients in Acute and Subacute Hospitals in Northumberland and North Tyneside
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Oral Health
Lead sponsor: Northumbria Healthcare NHS Foundation Trust
Sponsor class: OTHER
First posted: 2017-07-11
Enrollment: 35
Sex: ALL
Minimum age (years): 70
Standard ages: OLDER_ADULT
Observational model: OTHER
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: older adults admitted to elderly care wards within the trust. The hospital sites to be included are - NSECH, North Tyneside, Wansbeck, Hexham, Haltwhistle, Morpeth, Blyth, Alnwick and Berwick.

Brief summary: To provide a point-in-time measurement of the oral health of elderly inpatients across the trust (elderly defined here as over 70 years). This will provide information about the number of teeth, need for restorative and periodontal treatment, and extractions, the health of the oral mucosa, quality of any dentures and hygiene of the teeth and dentures.

Detailed description: Such information will allow identification of any problems with oral health in this hospital population, thereby allowing development of strategies and protocols for managing these problems. There have been a number of studies examining these variables in elderly residents in care homes and a few in long term hospital settings (over 1 year admission), but only one in the UK previously in acute hospitals. Therefore the published literature is sparse, and requires further data collection. The oral health of the elderly, but particularly the institutionalized, is increasingly recognised for its important relationships with general health, wellbeing and quality of life. This study will provide useful information to address these concerns.

Eligibility criteria: Inclusion Criteria:

* age 70 or over and admitted to geriatric ward within the study area, able to consent

Exclusion Criteria:

* unable to consent, aged under 70

Primary outcomes:
measure: level of oral hygiene
timeFrame: 1 month
Secondary outcomes:
measure: age
timeFrame: 1 month
measure: gender
timeFrame: 1 month
measure: condition of oral mucosa
timeFrame: 1 month
measure: number of broken and decayed teeth
timeFrame: 1 month
Other outcomes:
Locations:
city: Cramlington
country: United Kingdom
facility: Northumbria Hospitals NHS
Study officials:
affiliation: Northumbria Hospitals NHS Foundation Trust
name: Ben J Steel
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00936637: Effects on Growth of an Extensively Hydrolyzed Formula Fed to Term
Official title: A 16-Week Growth Study of an Extensively Hydrolyzed Infant Formula, 3 Months Treatment and 1 Month Follow-up for a Duration of 4 Months.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Growth
Lead sponsor: Perrigo Nutritionals
Sponsor class: INDUSTRY
First posted: 2009-07-10
Enrollment: 35
Sex: ALL
Minimum age (years): 1
Maximum age (years): 21
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP

Brief summary: The purpose of this study is to assess growth in infants who are fed an extensively hydrolyzed formula.


Eligibility criteria: Inclusion Criteria:

* At birth:

  * Healthy, term (37-42 weeks) infant
  * Weight for length between the 10th and 90th percentile according to the National Center for Health Statistics (NCHS) growth charts
* At time of enrollment:

  * \< or = 21 days post-natal age
  * Weight for length between the 10th and 90th percentile according to the National Center for Health Statistics (NCHS) growth charts
  * Exclusively formula fed
  * Written informed consent of parent/guardian

Exclusion Criteria:

* At the time of enrollment: partially human-milk fed; fed baby/solid foods
* Conditions requiring feedings other than those specified in the protocol
* Documented or suspected cow's milk allergy and/or soy protein allergies
* Major congenital deformities
* Suspected or documented systemic or congenital infections
* Evidence of cardiac, respiratory, hematological, gastrointestinal, or other systemic diseases
* Participation in any other clinical trial

Primary outcomes:
measure: An extensively hydrolyzed formula is nutritionally adequate for normal growth of healthy full-term infants
timeFrame: 16 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Charlottesville
country: United States
facility: University of Virginia
state: Virginia
Study officials:
affiliation: Perrigo Nutritionals
name: Cynthia M Barber, PhD
role: STUDY_DIRECTOR
References:
Clinical trial NCT01590537: Non-interventional Study of Long-term Intrauterine Contraceptives Acceptability and User Satisfaction
Official title: Prospective Multicentre Non-interventional Comparative Study of Long-term Intrauterine Contraceptives Acceptability and User Satisfaction
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Contraception
Keywords: non-interventional
Mirena
Contraception
Russian Federation
Lead sponsor: Bayer
Sponsor class: INDUSTRY
First posted: 2012-05-03
Enrollment: 2348
Sex: FEMALE
Minimum age (years): 20
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Females who plan long-term contraception and meet criteria of inclusion and exclusion.

Brief summary: This is local prospective, non-interventional multi-center comparative study. Primary study objective is evaluation of the user satisfaction with Mirena or Copper IUD up to 1 year after insertion ( patient assessment questionnaire) in daily practice. For each patient, the treating gynecologist documents demographics, medical data, safety parameters and treatment signs and symptoms at an initial visit and one or two follow-up visit(s).


Eligibility criteria: Inclusion Criteria:

* Women 20-40 years old
* Parity ≥ 1 child
* Requesting long-term contraception
* Written informed consent.

Exclusion Criteria:

* in accordance with the current leaflet

Primary outcomes:
measure: User satisfaction of the contraception method with Mirena or Copper IUD
timeFrame: up to 12 months
Secondary outcomes:
measure: Safety evaluation of Mirena or Copper IUD in routine practice Safety parameters include number of AEs, severity,relationship to Mirena or Cooper IUD
timeFrame: up to 12 months
measure: Contraceptive reliability of Mirena or Cooper IUD in routine practice ( fixing number of pregnancies)
timeFrame: up to 12 months
measure: Continuation/discontinuation rate ( number of cases with contraceptive method continuation and discontinuations)
timeFrame: up to 12 months
measure: Relationship between different parameters and women preferences in choosing Mirena or Cooper IUD as their contraceptive method ( demographic parameters, age group, residence, reproductive history and plans, etc.) using patients questionnaire
timeFrame: up to 12 months
Other outcomes:
Locations:
city: Many Locations
country: Russian Federation
Study officials:
affiliation: Bayer
name: Bayer Study Director
role: STUDY_DIRECTOR
References:
Clinical trial NCT05640037: Urine Interleukin-37 as a Biomarker of Mortality Risk in Patients With Sepsis
Official title: Urine Interleukin-37 as a Biomarker of Mortality Risk in Patients With Sepsis
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Sepsis
Keywords: sepsis
interleukin-37
biomarker
Lead sponsor: Zhongnan Hospital
Sponsor class: OTHER
First posted: 2022-12-07
Enrollment: 99
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: ICU admission with a suspicion of infection

Brief summary: This study aims to evaluate the efficacy of IL-37 as a biomarker to predict mortality risk in adults with sepsis.

Detailed description: Sepsis patients admitted in the Department of Critical Care Medicine, Zhongnan Hospital will be included.

There are three groups of patients in this study: control group, sepsis group and septic shock group.

The interleukin-37 (IL-37) concentration in urine was analyzed in the day 1, 2, 4, 6.

Additionally, IL-37 concentration between blood stream infection groups and non-infection groups were analyzed. IL-37 concentration between survivors and non-survivors were also compared. IL-37 concentration were followed from day 1, 2, 4, 6.The correlation between the concentration of IL-37, IL-1β, IL-6、IL-10 and TNF-α were analyzed. Furthermore, the investigators will determine the correlation between the concentration of IL-37, sepsis associated organ dysfunction, 28-day mortality. Lastly, the predictive value of IL-37 to sepsis associated organ dysfunction and prognosis were explored.

Eligibility criteria: Inclusion Criteria:

1. Age 18 years or older
2. Expected length of stay\>24 hours in intensive care unit (ICU)
3. Sequential organ failure assessment (SOFA) score ≥ 2 on ICU admission with a suspicion of infection

Exclusion Criteria:

1. anuria
2. ICU readmission in 28 days

Primary outcomes:
measure: 28-day all-cause mortality
timeFrame: 28 day
Secondary outcomes:
measure: ICU all-cause mortality
timeFrame: 28 day
measure: ICU length of stay
timeFrame: 28 day
measure: Hospital length of stay
timeFrame: 28day
Other outcomes:
Locations:
city: Wuhan
country: China
facility: Zhongnan Hospital of Wuhan University
state: Hubei
Study officials:
affiliation: Wuhan University
name: Dawei Wang, MD
role: STUDY_CHAIR
References:
Clinical trial NCT06955637: Removable Devices in Overjet Reduction
Official title: Comparison Between Removable Devices in Overjet Reduction: a Randomised Open Label Clinical Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Skeletal Class II Malocclusion
Dental Overjet
Lead sponsor: University of L'Aquila
Sponsor class: OTHER
First posted: 2025-05-02
Enrollment: 50
Sex: ALL
Minimum age (years): 9
Maximum age (years): 15
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The goal of this clinical trial si to compare two removable devices used to treat the mandibular retrusion in growing patients.

The main questions it aims to answer are:

* the efficacy of the two devices in the reduction of the overjet
* the neuromuscolar effects developed on the stomatognatic system Participants will be instructed in the use and maintenance of the devices and will be checked every 15-30 days for one year.


Eligibility criteria: Inclusion Criteria:

* skeletal class II relationship,
* complete eruption of upper first premolars
* presence of unilateral or bilateral cross bite (falling within grade 3 IOTN index).

Exclusion Criteria:

* IOTN (INDEX OF ORTHODONTIC TREATMENT NEED) index \> 4;
* presence of epilepsy,
* systemic disease,
* TMD, or periodontal disease;
* lack of written informed consent from a parent or legal guardian.

Primary outcomes:
measure: Changes in the horizontal distance between the upper and lower incisors
timeFrame: 12 months
Secondary outcomes:
Other outcomes:
Locations:
city: L'Aquila
country: Italy
facility: Dipartimento MESVA
state: Italia
Study officials:
References:
Clinical trial NCT01879137: Copeptin After Arginine Infusion in Polyuria-Polydipsia Syndrome
Official title: Copeptin After Arginine Infusion for the Differential Diagnosis of the Polyuria-Polydipsia Syndrome ''The CARGO-Study''
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Healthy
Polyuria-polydipsia Syndrome
Keywords: Copeptin
Arginin stimulation test
Lead sponsor: University Hospital, Basel, Switzerland
Sponsor class: OTHER
First posted: 2013-06-17
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Healthy adults Patients with polyuria-polydipsia syndrome

Brief summary: the purpose of the study is to investigate whether arginine infusion is a new tool to differentiate patients with diabetes insipidus, primary polydipsia and healthy subjects.


Eligibility criteria: Inclusion Criteria:

1. Age over 18 years
2. No medication except hormonal contraception

Exclusion Criteria:

1. Evidence of any acute illness
2. Subjects refusing or unable to give written informed consent
3. Pregnancy
4. Any evidence of disordered drinking habits and diuresis

Primary outcomes:
measure: Discriminative value of copeptin after arginine infusion in the differential diagnosis of polyuria-polydipsia syndrome.
timeFrame: up to 120 minutes after the Arginine infusion.
Secondary outcomes:
Other outcomes:
Locations:
city: Basel
country: Switzerland
facility: University Hospital Basel
state: Basel-Stadt
Study officials:
affiliation: University Hospital, Basel, Switzerland
name: Mirjam Christ-Crain, Prof. MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02894632: MR Compatible Accelerometer for Respiratory MOTion Measurement
Official title: MR Compatible Accelerometer for Respiratory MOTion Measurement
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Heart Disease
Keywords: MRI
Motion
Respiratory movement
Artifacts correction
Lead sponsor: Central Hospital, Nancy, France
Sponsor class: OTHER
First posted: 2016-09-09
Enrollment: 24
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: A novel magnetic resonance (MR) compatible accelerometer for respiratory motion sensing (MARMOT) has been developed as a surrogate of the vendors' pneumatic belts. The aim is to model and correct respiratory motion for free-breathing thoracic-abdominal MR imaging and to simplify patient installation.

Detailed description: Respiratory motion is a serious problem in the acquisition of high-quality thoracic/abdominal magnetic resonance (MR) images. Various methods have been proposed to compensate the motion-induced artefacts, including breathholding, respiratory gating and model-driven motion correction.

Breath-holding is the simplest among the three. However this conventional clinical method induces various problem, including inefficient use of scanners, inconsistent organ position between each breath-hold, imaging an altered physiological status and patient inconvenience especially for those who suffer from respiration difficulties. Free-breathing MR acquisition has therefore become of great clinical interest recently.

The investigators intend to examine the efficacy of the MARMOT sensors for:

* modelling and predicting the respiratory motions in abdominal scans,
* correcting for the respiratory motion in a cardiac cine scan, via a reconstruction-based method.

Eligibility criteria: Inclusion Criteria:

* To not have cardiac, hepatic or renal pathology
* To be more than 18
* To be enrolled in a social security plan
* To have signed an informed consent
* To have preliminary medical examination

Exclusion Criteria:

* Contraindication: implantable devices (pacemakers, defibrillators, cochlear implants, etc.), metallic foreign bodies
* Impossibility to undergo MRI : claustrophobia, morbid obesity
* Pregnancy or risk of pregnancy
* Patient under a measure of legal protection

Primary outcomes:
measure: Respiratory movement using respiratory belts
timeFrame: four months
measure: Respiratory movement using MARMOT sensors
timeFrame: four months
measure: Respiratory movement using real-time MR images
timeFrame: four months
Secondary outcomes:
measure: Subjective quality (marks between 1 (the best) and 3 (the worst) of the reconstructed MR images)
timeFrame: four months
Other outcomes:
Locations:
city: Vandoeuvre-lès-Nancy
country: France
facility: Centre Hospitalier Régional Universitaire de Nancy Brabois
Study officials:
affiliation: Inserm - U947
name: Laurent Bonnemains, Dr
role: PRINCIPAL_INVESTIGATOR
References: